Saturday 17 October 2026 Export NEO’s income statement to Excel — free account

NeoGenomics, Inc.

NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 11.2%, EPS grew 105.7%, free cash flow fell 16.2% and total debt rose 10.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

16.65 0.60 −3.48%

Follow NEO

Alert me

Market cap: $2.2B
P/E: 0.0×
Fwd P/E: −24.5×
Dividend yield: —
F-score: 4/9
Altman Z: 1.79
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.97

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	1	—	—	—	—	2	—	1	—	—

Insider Ownership 2.80%

Capital & Financial Ratios $m

Market Cap 2,220.00

Revenue 766.30

Net Income (51.88)

Free Cash Flow (5.29)

Net Debt 232.73

Current Ratio 3.60

Debt/Equity 0.48

P/E ratio 0.00

Fwd P/E (24.50)

P/S ratio 2.82

P/B ratio 2.75

Past 5Y EPS Growth —

This Y EPS Growth 56.06%

Next Y EPS Growth 83.01%

Next Y revenue growth 10.66%

Next 5Y EPS Growth 55.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 29.60%

10-year low 10-year high

P/B against its own 10 years 45.60%

10-year low 10-year high

EV/Sales against its own 10 years 37.82%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	415	387	160	146
Receivables	131	151	159	175
Inventory	24	27	29	27
Other	8	12	7	10
	597	596	376	381

	2023	2024	2025	Q'26
Payables	20	22	23	21
ST’ Debt	—	201	—	—
Other	2	0	1	0
	96	301	88	106

Compound Annual Growth %

	10y	5y	3y
Sales	21.97%	10.35%	12.58%
Cash Flow	(1.99%)	29.07%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	14.85%	3.80%	(5.71%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	187	202	—	—	—
’25	168	181	188	190	727
’24	156	165	168	172	661
’23	137	147	152	156	592
’22	117	125	129	139	510
’21	116	122	121	126	484
’20	106	87	125	126	444

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	20	—	—	—
’25	(25)	20	9	1	5
’24	(26)	14	9	10	7
’23	(13)	(2)	(5)	18	(2)
’22	(29)	(17)	(16)	(4)	(66)
’21	2	(1)	(8)	(20)	(27)
’20	(7)	2	1	6	1

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	12	—	—	—
’25	(30)	14	1	(4)	(20)
’24	(31)	1	(2)	(2)	(34)
’23	(23)	(9)	(10)	11	(31)
’22	(37)	(15)	(24)	(8)	(85)
’21	(14)	(23)	(23)	(32)	(91)
’20	(12)	(3)	(7)	(6)	(28)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.13)	0.02	—	—	—
’25	(0.20)	(0.35)	(0.21)	(0.08)	(0.84)
’24	(0.21)	(0.15)	(0.14)	(0.12)	(0.62)
’23	(0.25)	(0.19)	(0.15)	(0.11)	(0.70)
’22	(0.40)	(0.28)	(0.30)	(0.18)	(1.16)
’21	(0.19)	0.59	(0.17)	(0.34)	(0.07)
’20	(0.07)	(0.06)	0.02	0.13	0.04

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5.49	7.12	7.08	12.04	20.47	29.66	6.00	8.71	12.77	4.72	Analyst estimates 2026–2028 Powerpack
	High	9.88	11.63	19.04	30.00	57.07	61.57	35.34	21.22	19.00	19.11
People
People	Employees	968	1,030	1,500	1,700	1,700	2,000	2,100	2,100	2,200	2,500
	Revenue/emp, $m	0.24	0.23	0.18	0.24	0.26	0.24	0.24	0.28	0.30	0.29
Income, $m
Income, $m	Revenue	232	240	277	409	444	484	510	592	661	727
	Gross margin, %	42.32	42.44	45.99	48.15	41.83	38.62	36.86	41.34	43.92	43.21
	EBT	(8)	(3)	4	4	(14)	(15)	(159)	(97)	(81)	(110)
	EBT margin, %	(3.38)	(1.10)	1.38	0.89	(3.16)	(3.11)	(31.26)	(16.41)	(12.21)	(15.16)
	Net income	(6)	0	3	8	4	(8)	(144)	(88)	(79)	(108)
	Depreciation	27	23	22	31	40	56	72	75	75	70
Per share, $
Per share, $	Revenue	2.99	3.02	3.23	4.07	4.09	4.04	4.10	4.71	5.22	5.68
	Earnings	(0.39)	(0.14)	0.03	0.08	0.04	(0.07)	(1.16)	(0.70)	(0.62)	(0.84)
	Cash flow	0.28	0.23	0.52	0.23	0.01	(0.22)	(0.53)	(0.02)	0.06	0.04
	Capex	(0.10)	(0.17)	(0.17)	(0.20)	(0.27)	(0.53)	(0.15)	(0.23)	(0.32)	(0.19)
	Free cash flow	0.18	0.05	0.36	0.03	(0.25)	(0.76)	(0.68)	(0.24)	(0.27)	(0.15)
	Book value	2.11	2.17	3.74	5.05	6.39	9.24	8.03	7.50	7.12	6.53
	Shares, m	78	79	86	100	109	120	124	126	127	128
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	417.86	1,794.67	0.00	0.00	0.00	0.00	0.00
	P/S	2.89	2.88	3.90	7.19	13.15	8.45	2.22	3.38	3.16	2.07
	P/B	4.09	4.03	3.37	5.79	8.42	3.69	1.13	2.13	2.31	1.80
	EV/Sales	3.27	3.25	4.25	7.01	12.89	8.50	2.42	3.60	3.39	2.60
	EV/FCF	54.37	179.44	38.58	858.01	(207.22)	(45.32)	(14.55)	(69.39)	(65.86)	(95.87)
Cash, $m
Cash, $m	Operating cash flow	21	18	45	23	1	(27)	(66)	(2)	7	5
	Capex	(8)	(14)	(14)	(20)	(29)	(64)	(19)	(29)	(41)	(25)
	Free cash flow	14	4	30	3	(28)	(91)	(85)	(31)	(34)	(20)
Balance, $m
Balance, $m	Working capital	41	49	43	227	376	594	515	501	295	288
	Total debt	101	100	106	100	177	540	542	538	541	342
	Net debt	89	87	96	(73)	(119)	25	104	123	154	182
	Shareholders’ equity	164	172	320	507	694	1,108	998	942	902	837
Returns, %
Returns, %	ROA	(8.95)	(3.21)	1.43	1.32	0.49	(0.58)	(7.99)	(5.14)	(4.74)	(7.21)
	ROIC	0.53	0.70	1.51	1.87	(1.52)	(6.55)	(8.94)	(6.33)	(5.45)	(7.11)
	ROE	(16.51)	(6.52)	2.47	1.93	0.69	(0.93)	(13.70)	(9.07)	(8.54)	(12.42)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BLLN BillionToOne, Inc.	$4.9B	95.0×	99.4×	+64.40% (above 0%: growing)	n/m	+400.65% (above 0%: growing)	70.45%	5.03%	Compare
ADPT Adaptive Biotechnologies Corporation	$4.1B	— (loss-making)	— (loss-making)	+21.53% (above 0%: growing)	n/m	+42.04% (above 0%: growing)	71.82%	(22.04%)	Compare
VCYT Veracyte, Inc.	$3.6B	29.9×	45.1×	+15.49% (above 0%: growing)	n/m	+32.95% (above 0%: growing)	72.21%	15.29%	Compare
CDNA CareDx, Inc.	$3.5B	29.7×	2,967×	+52.23% (above 0%: growing)	n/m	+223.42% (above 0%: growing)	73.50%	85.81%	Compare
NEO NeoGenomics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+11.21% (above 0%: growing)	n/m	−16.18% (below 0%: shrinking)	45.56%	(4.85%)
WGS GeneDx Holdings Corp.	$2.1B	— (loss-making)	— (loss-making)	+11.44% (above 0%: growing)	n/m	−585.59% (below 0%: shrinking)	68.37%	(15.25%)	Compare
PSNL Personalis, Inc.	$1.7B	— (loss-making)	— (loss-making)	+29.96% (above 0%: growing)	n/m	−123.46% (below 0%: shrinking)	21.21%	(150.25%)	Compare
OPK OPKO Health, Inc.	$1.2B	— (loss-making)	— (loss-making)	+4.32% (above 0%: growing)	n/m	+46.46% (above 0%: growing)	48.92%	(4.26%)	Compare
CSTL Castle Biosciences, Inc.	$1.0B	— (loss-making)	— (loss-making)	+20.14% (above 0%: growing)	n/m	−43.33% (below 0%: shrinking)	77.11%	(2.96%)	Compare
Median of peers	$2.8B	29.9×	99.4×	+20.83%	—	+37.50%	71.13%	(3.61%)

All 52 Diagnostics & Research stocks →

NeoGenomics, Inc. (NEO) key facts

Strength: NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
NeoGenomics, Inc. (NEO) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NEO traded at $16.65, a market capitalization of $2.2 billion.
Return on equity was −12.4% and debt-to-equity 0.48.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.79 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.